Teva Racks Up Outside Support for Redo of Skinny Label Ruling

Generic drug makers, nonprofit groups, professors, and a former congressman behind the Hatch-Waxman Act have lined up in support of Teva Pharmaceutical Industries Ltd.‘s request for the full Federal Circuit to review a drug labeling decision.

In October, a divided panel of the U.S. Court of Appeals for the Federal Circuit reinstated a $235 million verdict against Teva for infringing GlaxoSmithKline Plc‘s patent on the heart drug Coreg. The label on Teva’s generic version specifically carved out the patented uses of the drug, but the majority held the company induced doctors to infringe.

Chief Judge Sharon Prost dissented, ...